

CURRICULUM VITAE**NAME** Roger L. Albin, M.D.**EDUCATION**

05/1973 Shadyside Academy, Pittsburgh, PA
05/1977 Oberlin College, Oberlin, Ohio; B.A. (Biology)
06/1982 University of Pittsburgh, Pittsburgh, PA; M.D.

POSTDOCTORAL TRAINING

07/1982-06/1983 University of Michigan, Ann Arbor, MI
Department of Internal Medicine, Internship
07/1983-06/1986 University of Michigan, Ann Arbor, MI
Department of Neurology, Residency
07/1986-06/1988 University of Michigan, Ann Arbor, MI
Department of Neurology, Fellowship

ACADEMIC APPOINTMENTS

07/1988-08/1989 Instructor, Department of Neurology
09/1989-08/1994 Assistant Professor, Department of Neurology
09/1994-08/2000 Associate Professor, Department of Neurology
09/2000-present Professor, Department of Neurology
09/1988-present Member, Neuroscience Program Faculty
09/1995-present Director, Neuroscience Research, Ann Arbor VAMC GRECC
09/1999-08/2001 Associate Director, Neuroscience Graduate Program

CONSULTING POSITIONS

1990-1996 Science Council, Huntington's Disease Society of America
1993-1996 Chair; Science Council Huntington's Disease Society of America
1992 External Reviewer, Johns Hopkins University, Huntington's

| | |
|---------------------------------|--|
| | Disease Center |
| 1996-present Foundation | Professional Advisory Board, Michigan Parkinson's |
| 1996-present | Publications Committee, Huntington's Study Group |
| 1994 | HAB 1.1A Study Section, NASA, Ad Hoc Reviewer |
| 1995, 1996 | MRC of Canada, Ad Hoc Reviewer |
| 1995, 1996, 1997 | Wellcome Trust, Ad Hoc Reviewer |
| 1996 | Board of Scientific Councilors, NIMH, Ad Hoc Reviewer |
| 1997 | NSD-B Study Section, Ad Hoc Reviewer |
| 1997, 1998, 1999 2002 | Health Research Council of New Zealand |
| 1995, 1997, 1998, 1999, 2005 | Telethon Combatti La Distrofia Muscolare e Le Altre Malattie Genetiche |
| 1997, 1999, 2000, 2001 | Ad Hoc Reviewer, Office of External Reviews, VA |
| 1999, 2000 | Ad Hoc Reviewer, Science Council, Huntington's Disease Society of America |
| 2000 | NSD-A Study Section, Ad Hoc Reviewer |
| 2001-2003 | Research Grants Sub-Committee, Huntington's Disease Society of America |
| 2000-present | Huntington Study Group Credentials Committee |
| 2003 | BDCN-1 Study Section, Ad Hoc Reviewer |
| 2003-present | CND Study Section, Regular Member |

EDITORIAL BOARDS

| | |
|--------------|---|
| 1996-2001 | Lancet Neurology Network Commentary |
| 1997-present | Experimental Neurology |
| 2000-2002 | Medlink Neurology; Associate Editor, Movement Disorders |

| | |
|--------------|-------------------------|
| 2003-present | Movement Disorders |
| 2003-present | Neurology |
| 2004-present | Neurobiology of Disease |

SCIENTIFIC ACTIVITIES

Ad Hoc Reviewer

Annals of Neurology
Archives of Neurology
Behavioral Brain Research
Brain Research
Epilepsy Research
European Journal of Neuroscience
Experimental Neurology
Human Molecular Genetics
Journal of Clinical Investigation
Journal of Comparative Neurology
Journal of Neurochemistry
Journal of the Neurological Sciences
Journal of Neurology, Neurosurgery, and Psychiatry
Journal of Neuroscience
Life Science
Molecular Neurobiology
Movement Disorders
Nature Medicine
Neurobiology of Disease
Neurology
Neuroscience
Neuroscience Letters
PNAS

GRANT SUPPORT

Current

PO1 NS15655; Kirk Frey, MD, PhD, Program Director
PET Study of Biochemistry and Metabolism of CNS
Total Project Period: 7/1/00 – 6/31/06
Project 4: Dopamine Synaptic Mechanisms in Tourette Syndrome
Roger L. Albin, M.D., Project Director
Direct Costs: \$54,903 (7/1/00-6/31/01)

National Institutes of Health
U10 NS44504; Roger L. Albin, MD, Project Director
Michigan Parkinson's Disease Clinical Center
Total Project Period: 7/1/02 – 6/30/07
Direct Costs: \$66,859 (7/1/02 – 6/30/03)

National Institutes of Health
PO50 AG08671, Sid Gilman, M.D., Program Director
"Michigan Alzheimer's Disease Research Center"
Total Project Period: 6/1/05 – 5/31/10
Core: "Neuropathology"
Roger L. Albin, M.D., Senior Investigator
Direct Costs: \$137,587 (6/1/05 – 5/31/10)
Project 3: "Differentiating Degenerative Dementia with DTBZ-PET"
Roger L. Albin, M.D., Project Director
Direct Costs: \$125,000 (6/1/05 – 5/31/10)

National Institutes of Health
1KO8 NS45180; Matthew T. Lorincz, MD, PhD, Principal Investigator; Roger L. Albin, MD, Mentor
Embryonic Stem Cell Model of Polyglutamine Disease
Total Project Period: 7/1/03 – 6/30/08
Direct Costs: \$153,950 (7/1/03 – 6/30/04)

VA Merit Program
Roger L. Albin, M.D, Project Director
NR2B Mediated Neurotoxicity in Murine Huntington Disease Model
Total Project Period: 10/01/04 - 09/30/09
Direct Costs: \$750,000 (\$150,000 per year)

Huntington Study Group/NIHGR
Pilot Huntington At Risk Observational Study (PHAROS)
Ira Shoulson, M.D., Project Director
Ninith Kartha, M.D., Site Investigator
Roger L Albin, M.D., Rating Investigator
Direct Costs: \$17,142 (9/1/99 – 4/30/06)

University of Rochester (NIH)
Coenzyme Q10 (CoQ) in Huntington's Disease (2CARE)
Roger L. Albin, M.D., Site Investigator
Total Project Period: 12/01/05 - 11/30/10 (tentative dates)
Direct Costs: \$80,951

Huntington's Disease Society of America
NR2B Mediated Toxicity in Murine Huntington's Disease
Roger L. Albin, M.D., Project Director
Total Project Period: 07/01/05 - 06/30/06

Direct Costs: \$50,000

National Institutes of Health
RO3 NS054810; Roger L. Albin, M.D., Principal Investigator
Evaluating Striatal Function in a Murine HD Model
Total Project Period: 06/01/06 – 05/31/08
Direct Costs \$137,119 (06/01/06 – 05/31/08)

CERTIFICATION AND LICENSURE

Michigan (1983)
Diplomate of American Board of Psychiatry and Neurology (1988)
Michigan State Youth Soccer Association E Coaching License

MILITARY SERVICE

None

HONORS AND AWARDS

Alpha Omega Alpha
M.D. Cum Laude
Listed in Best Doctors in America: 1999 Edition

MEMBERSHIPS AND OFFICES IN PROFESSIONAL SOCIETIES

American Academy of Neurology
American Association for the Advancement of Science
American Neurologic Association
Huntington's Study Group
Society for Neuroscience

TEACHING ACTIVITIES

Co-Director of Neuroscience 731; "Clinical Neuroscience"
Director, Neuroscience 602; "Core Course In Neuroscience", 1999-2001

Thesis Committee Membership

| | |
|--------------------|------------------------------|
| Anthony Kincaid | Department of Anatomy |
| Eileen Curran | Neuroscience Program |
| Howard C. Cromwell | Biopsychology Program |
| David Rock | Neuroscience Program |
| Claudia Testa | Neuroscience Program |
| Sarah Turgeon | Neuroscience Program (Chair) |

| | |
|-------------------------|------------------------------|
| Paul Mermelstein | Neuroscience Program |
| Jon Galasso | Neuroscience Program |
| Rowena Johnston | Biopsychology Program |
| Jennifer Feeley Kearney | Neuroscience Program (Chair) |
| Douglas McColloch | Department of Mathematics |
| Kevin Haas | Neuroscience Program |
| David Hinkle | Neuroscience Program |
| Michelle Ostrander | Neuroscience Program |
| Matt Bianchi | Neuroscience Program |
| Rita Cowell | Neuroscience Program |
| Virginia Savage | Neuroscience Program |
| David Buchner | Human Genetics |
| Susan Ferguson | Neuroscience Program |
| Valeries Drews | Human Genetics |
| Eunju Seong | Neuroscience Program |
| Emily Jutkiewicz | Pharmacology |
| Dorothy Jones | Neuroscience Program |
| Elyse Kemmerer | Neuroscience Program |
| Chris Pacheco | Neuroscience Program |

Lectures

M2 Neuroscience Sequence: Basal Ganglia Disorders
Neuroscience 721: GABA/Glutamate
M4 Clinical Pharmacology Course: Treatment of Parkinson's disease
Human Neuroanatomy Course – Basal Ganglia Pathophysiology

EXTRAMURAL INVITED PRESENTATIONS

Mini-Symposium on Genetic Diseases of the Nervous System; University of Cincinnati (4/6/89)

World Federation of Neurology Working Group on Huntington's Disease; Vancouver, Canada (6/28/89)

Cajal Club Symposium on the Basal Ganglia; Philadelphia (4/22/90)

Neurology Grand Rounds, University of Texas Health Science Center; San Antonio (5/24/90)
Symposium on *In Vivo* Imaging of Neurotransmitter Functions in Brain, Heart, and Tumors; Montreal, Canada (8/24/90)

Clinical Neurochemistry Course: American Academy of Neurology; Boston (5/24/91)

Excitatory Amino Acids in the Basal Ganglia: 2nd International Congress on Amino Acids and Analogues; Vienna, Austria (8/7/91)

The Basal Ganglia in the 90's: Society for Neuroscience (11/11/91)

Excitatory Amino Acids 1992: Fidia Research Foundation; Yosemite (2/20/92)

The Functional Anatomy of Basal Ganglia Disorders: Parke-Davis/Warner-Lambent (11/4/92)

The Other GABA Receptor: GABA_B: Southern Illinois University Department of Pharmacology (6/2/93)

Neurology Grand Rounds, University of Tennessee (2/18/94)

Keynote Speech, Huntington's Disease Society of America Annual Convention (7/30/94)

The Functional Anatomy of Basal Ganglia Disorders and Pathophysiology of Huntington's Disease, Banff Conference (12/94)

Movement Disorders, Grand Rapids Family Practice Residency Annual Alumni Conference, Grand Rapids, MI (5/12/95)

Huntington's Disease, Washington University School of Medicine Dept. of Anatomy and Neurobiology Seminar, St. Louis, MO (3/18/96)

Excitatory Amino Acids in the Basal Ganglia, Washington University School of Medicine Department of Neurology Seminar, St. Louis, MO (3/18/96)

Excitatory Amino Acids in the Basal Ganglia: Focus on AMPA and Metabotropic Receptors, University of Alabama at Birmingham Neurobiology Research Center, Birmingham, AL (7/26/96)

The Functional Anatomy of Basal Ganglia Disorders, Neurofest 1996, University of Cincinnati (10/4/96)

Huntington's Disease and Excitotoxicity; World Federation of Neurology Meeting, Buenos Aires, Argentina (9/16/97)

Update on Neurotransmitter Anatomy and Pharmacology; Movement Disorders Course, American Academy of Neurology Meeting, Minneapolis (5/2/98)

Update on Neurotransmitter Anatomy and Pharmacology; Movement Disorders Course, American Academy of Neurology Meeting, Toronto (4/18/99)

Striatal and Subthalamic mGluRs, The Chicago Medical School, Chicago (4/27/99)

Glutamate-Dopamine Interactions, International Meeting on Neurotoxicology, Degeneration and Protection in Brain Disease States, Mojacar, Spain (10/18/99)

Models of Basal Ganglia Dysfunction – Alessandro Agnoli Lecture, Parkinson's Disease and Other Movement Disorders 2000, Pavia, Italy (5/28/00)

Initial Treatment of Parkinson's Disease – Parkinson's Disease 2001, East Lansing (9/12/01)

Pathophysiology and Management of Parkinson's Disease, Society for Neurosurgical Anesthesia and Critical Care, New Orleans (10/12/01)

Dopaminergic and cholinergic vesicular imaging in hyperkinetic movement disorders. Dopamine 2002, Portland (7/14/02)

Parkinson's Plus Syndromes. Michigan Parkinson Foundation State Wide Meeting, Lansing (9/15/02)

Huntington Disease: Human and Murine Pathology, University of Southern California (11/21/02)

Initial Agonist Therapy of Parkinson's Disease: A Critique. Neurology Grand Rounds, Michigan State University, East Lansing (04/17/03)

Huntington Disease: Human and Murine Pathology. Neuroscience Program Seminar, Michigan State University, East Lansing (04/17/03)

mGluRs: A Novel Target for Pharmacotherapy in Parkinson's Disease. MSTP Program Seminar, Michigan State University, East Lansing (04/17/03)

Huntington Disease: Human and Murine Pathology. Neurology Grand Rounds, Medical College of Ohio, Toledo (5/8/03)

Imaging VMAT2 in Neurological Disease: A Biomarker of Nigrostriatal Projection Neuron Integrity. Imaging in Parkinson's Disease Meeting, Washington DC (9/9/03).

Huntington Disease: Human and Murine Pathology. Neurology Grand Rounds, Medical College of Wisconsin, Milwaukee (9/19/03).

Initial Treatment of Parkinson's disease. Neurology Grand Rounds, Henry Ford Health System, Detroit (11/10/03).

Genetics of Parkinson's Disease. Annual Michigan Genetics Symposium, Henry Ford Hospital, Detroit (5/7/04).

PSP and Related Disorders. Update on Parkinson's Disease, Essential Tremor, and Progressive Supranuclear Palsy, East Lansing, MI (10/08/04).

Genetics of Parkinson's Disease. Update on Parkinson's Disease, Essential Tremor, and Progressive Supranuclear Palsy, East Lansing, MI (10/08/04).

Increased Ventral Striatal Monoaminergic Innervation in Tourette's Syndrome. Tourette's Syndrome: The Self Under Siege. Society for Neuroscience Minisymposium, San Diego (8/25/04).

Movement Disorders. St. Joseph's Mercy Hospital Grand Rounds, Ypsilanti, MI (2/2/05)

Huntington Disease: Human and Murine Pathology. Wayne State University, Detroit, MI (2/22/05)

Initial Treatment of Parkinson's Disease. Neurology Grand Rounds, Medical College of Ohio, Toledo (3/17/05)

Parkinson's Disease. American Geriatric Society Core Curriculum. Orlando, FL (5/13/05)

Huntington Disease: Human and Murine Pathology. Dept. of Neurology Grand Rounds, University of Alabama at Birmingham, Birmingham AL (5/31/05)

Neurobiology of Tourette Syndrome. American College of Neuropsychopharmacology, Kona, HI (12/20/05).

Movement Disorders. Department of Internal Medicine Affiliated Hospital Visiting Program, McLaren Regional Medical Center, Flint, MI (1/20/06).

INTRAMURAL INVITED PRESENTATIONS

Medical Genetics Grand Rounds; University of Michigan (4/17/92)

Department of Anatomy Seminar Series; University of Michigan (6/18/92)

Institute of Gerontology Seminar Series; University of Michigan (12/15/92)

Parkinson's Disease, Annual Geriatric Medicine Course, University of Michigan Towsley Center for Continuing Medical Education (9/5/97)

Striatal Metabotropic Glutamate Receptors, Neuroscience Graduate Program Seminar; University of Michigan (2/16/98)

Parkinson's Disease Pathophysiology, Parkinson's Disease Update Course, University of Michigan Towsley Center for Continuing Medical Education (11/19/99)

Neurobiology of Parkinson's Disease. Annual Geriatric Medicine Course, University of Michigan Towsley Center for Continuing Medical Education (9/27/02).

Striatal Dysfunction: Behavior, Anatomy, and Neurodegeneration. Psychiatry Ground Rounds, University of Michigan (10/30/02)

mGluRs: A Novel Target for Pharmacotherapy in Parkinson's Disease. Advancing the Science of Neurologic Diseases: A Tribute to Sid Gilman, University of Michigan, Ann Arbor (03/08/03)

PET Studies of Hyperkinetic Movement Disorders. Annual GCRC Symposium. University of Michigan, Ann Arbor (4/12/03).

Response to Gomez-Lobo. Bioethics, Ancient and Modern. University of Michigan, Ann Arbor (9/21/03).

COMMITTEES AND ADMINISTRATIVE SERVICE

University of Michigan

| | |
|--------------|---|
| 1991-1994 | Geriatrics Research and Training Center: Research Operating Committee |
| 1991-present | Neurology Department Recruitment Committee |
| 1991-present | Neurology Department Clinical Affairs Committee |
| 1991-2003 | Neurology Department Medical Student Education Committee |
| 1991-present | Alzheimer's Disease Research Center Executive Committee |
| 1992-1993 | Medical School Focus Group on the Future of the Medical School |
| 1994-1999 | Neural and Behavioral Sciences Course Steering Committee |
| 1995 | Task Force on Graduate Education |
| 1996-2001 | Neuropathology Search Committee |
| 1996-1998 | Neuroscience Program Executive Committee |
| 1998-1999 | PIBS Curriculum Committee |
| 1999-2002 | Advisory Committee on Appointments, Promotions, and Tenure (ACAPT) |
| 2001-2002 | Chair, ACAPT |
| 2001-present | Joint Neuroscience Recruitment Committee |
| 1999-2000 | Neuroscience Advisory Task Force, Michigan Health and Aging Research and Development Initiative |
| 1999-2001 | PIBS Operating Committee |
| 2000-present | Neurology Department Appointments, Promotions, and Awards Committee (APAC) |
| 2001-present | Chair, Neurology Department APAC |
| 2001-2004 | Medical Scientist Training Program (MSTP) Operating Committee |
| 2001-2002 | Nuclear Medicine Division Chief Search Committee |
| 2002 | Department of Neurology Internal Review Committee, Chair |

BIBLIOGRAPHY**Articles****Peer Reviewed Publications**

1. Albin MS, Martinez-Agguire E, Albin RL. Tetrahydroaminoacridine (THA) II. Modifications of post-anesthetic emergence responses and anesthesia sleep-time in the human. Recent Progress in Anesthesiology and Resuscitation (Excerpta. Med. Int. Congr. Ser.) 1974, 347:147-149.
2. Hung TK, Albin MS, Brown TD, Bunegin L, Albin R, Jannetta PJ. Biomechanical responses to open experimental spinal cord injury. Surg. Neurol. 1975, 4:271-276.
3. Ellis CN, Gilbert M, Cotena KA, Albers JW, Ball RD, Albin RL, Silverman A, Voorhees JJ. Increased muscle tone during etretinate therapy. J. Am. Acad. Derm. 1986, 14:907-909.
4. Albin RL, Albers JW, Greenberg HS, Townsend JB, Lynn RB, Burke JM, Alessi, AG. Acute sensory neuropathy-neuronopathy from pyridoxine overdose. Neurology 1987, 37:1729-1732.
5. Greenamyre JT, Maragos WF, Albin RL, Penney JB, Young AB. Glutamate transmission and toxicity in Alzheimer's disease. Prog. Neuropsychopharmacol. And Biol. Psych. 1988, 12:421-430.
6. Albin RL, Bromberg MB, Penney JB, Knapp RH. Chorea and dystonia: A remote effect of carcinoma. Movement Disorders 1988, 3:162-169.
7. Albin RL, Silverman AK, Ellis CN, Voorhees JW, Albers JW. A new syndrome of axial muscle rigidity associated with etretinate therapy. Movement Disorders 198, 3:70-76.
8. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB. Differential loss of substance-P containing and enkephalin-containing striatal neurons in Huntington's disease. P.N.A.S., 1988, 85:5733-5737.
9. Albin RL. The pleiotropic gene theory of senescence:Supportive evidence from human genetic disease. Ethology and Sociobiology 1988, 9:371-382.
10. Albin RL, Young AB, Penney JB. Tetrahydro-9-aminoacridine (THA) interacts with the phencyclidine (PCP) receptor site. Neuroscience Letters 1988, 88:303-307.
11. Albin, RL, Young, AB. Somatosensory phenomena in Huntington's disease. Movement Disorders 1988, 3:343-346.
12. Young AB, Greenamyre JT, Hollingsworth Z, Albin R, D'Amato CJ, Shoulson I, Penney JB. NMDA receptor losses in putamen from patients with Huntington's disease. Science 1988, 241:981-984.

13. Albin RL, Aldridge JW, Young AB, Gilman S. Feline subthalamic nucleus neurons contain glutamate-like but not GABA-like or glycine-like immunoreactivity. Brain Res. 1989, 491:185-188.
14. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends in Neurosci. 1989, 12:366-375.
15. Albin, RL, Gilman S. Parasagittal zonation of GABA-B receptors in molecular layer of rat cerebellum. Eur. J. Pharm. 1989, 173:113-114.
16. Albin RL. The death of Nicholas Bolskonski: Neurology in Tolstoy's *War and Peace*. Arch. Neurol. 1990, 47:225-226.
17. Chu DCM, Albin RL, Young AB, Penney JB. Distribution, kinetics, and pharmacology of GABA(B) binding sites in the rat central nervous system. Neuroscience 1990, 34:341-358.
18. Albin RL, Young AB, Penney JB, Handelin B, Balfour R, Anderson KD, Markel DS, Tourtellotte WW, Reiner A. Striatal projection neuron and N-methyl-D-aspartate abnormalities in a case of presymptomatic Huntington's disease. New England Journal of Medicine 1990, 322:1293-1298.
19. Albin RL, Reiner A., Anderson KD, Penney JB, Young AB. Striatal and nigral neuron subpopulations in rigid Huntington's disease: Implications for the functional anatomy of chorea and rigidity-akinesia. Ann. Neurol. 1990, 27:357-365.
20. Albin RL, Albers JW. Long-term follow-up of pyridoxine induced acute sensory neuropathy-neuronopathy. Neurology 1990, 40(8):1319.
21. Makowiec RL, Albin RL, Cha JJ, Young AB, Gilman S. Two types of quisqualate receptor are reduced in human olivopontocerebellar atrophy cerebellar cortex. Brain Res. 1990, 523:309-312.
22. Albin RL, Makowiec RL, Hollingsworth Z, Dure LS, Penney JB, Young JB. Excitatory amino acid receptors in the periaqueductal gray of the rat. Neurosci. Lett. 1990, 118:112-115.
23. Vogel C. Albin RL, Albers JW. Lotus foot-drop. Neurology 1991, 41:605-606.
24. Pranzatelli MR, Albin RL, Cohen BH. Acute dyskinesias in young asthmatics treated with Theophylline. Ped. Neurol. 1991, 7(3):215-219.
25. Albin RL, Qin Y, Young AB, Penney JB, Chesselet MF. Preproenkephalin messenger RNA-containing neurons in striatum of patients with symptomatic and presymptomatic Huntington's Disease: An *in situ* hybridization study. Ann. Neurol. 1991, 30:542-549.
26. Albin RL, Price RH, Sakurai SY, Penney JB, Young AB: Excitatory and inhibitory amino acid binding sites in human dentate nucleus. Brain Res. 1991, 560:350-353.

27. Albin RL, Sakurai SY, Makowiec RL, Gilman S. Excitatory and inhibitory amino acid neurotransmitter binding sites in the cerebellar cortex of the pigeon (*Columba livia*). J. Chemical Neuroanatomy 1991, 4:429-437.
28. Albin RL, Sakurai SY, Makowiec RL, Higgins DS, Young AB, Penney JB. Excitatory amino acid, GABA_A, and GABA_B binding sites in human striate cortex. Cerebral Cortex 1991, 1:499-509.
29. Bazzett T, Becker JB, Albin RL. A novel device for chronic intracranial drug delivery via microdialysis. J. Neurosci. Methods 1991, 40:1-8.
30. Albin RL, Makowiec RL, Hollingsworth Z, Sakurai SY, Dure LS, Penney JB, Young AB. Excitatory amino acidergic pathways and receptors in the basal ganglia. Amino Acids 1991, 1:339-350.
31. Albin RL, Makowiec RL, Hollingsworth Z, Dure LS, Penney JB, Young AB. Excitatory amino acid neurotransmitter binding sites in the basal ganglia of the rat: A quantitative autoradiographic analysis. Neuroscience 1992, 46:35-48.
32. Albin RL, Reiner A, Anderson KD, Dure LS, Handelin B, Balfour R, Whetsell WO, Penney JB, Young AB. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease Ann. Neurol. 1992, 31:425-430.
33. Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology 1992, 42:733-738.
34. Kaatz KW, Bazzett T, Albin RL. A new simple myelin stain. Brain Res. Bull. 1992, 29:697-698.
35. Tallaksen-Greene SJ, Wiley RG, Albin RL. Localization of striatal excitatory amino acid binding site subtypes to striatonigral projection neurons. Brain Res. 1992, 594:165-170.
36. Albin RL, Gilman S. GABA_A, GABA_B and benzodiazepine binding sites in the cerebellar cortex of the red-eared turtle (*Pseudemys scripta*). Brain Res. 1992, 595:164-166.
37. Turgeon SM, Albin RL. Zinc modulates GABA_B binding in rat brain. Brain Res. 1992, 596:30-34.
38. Kincaid AE, Albin RL, Newman SW, Penney JB, Young AB. 6-Hydroxydopamine lesions of the nigrostriatal pathway alter the expression of glutamic acid decarboxylase mRNA in rat globus pallidus projection neurons. Neuroscience 1992, 51:705-718.
39. Albin RL, Hollingsworth Z, Sakurai SY, Gilman S. Inhibitory and excitatory amino acid neurotransmitter binding sites in cynomolgus monkey (*macaca fascicularis*) cervical spinal cord. Brian Res 1993, 604:354-357.

40. Bazzett TJ, Becker JB, Kaatz KW, Albin RL. Chronic intrastriatal dialytic administration of quinolinic acid produces selective neural degeneration. Exp Neurol 1993, 120:177-185.
41. Price RH, Albin RL, Sakurai SY, Polinsky RJ, Penney JB, Young AB. Cerebellar excitatory and inhibitory amino acid receptors in multiple system atrophy. Neurology 1993, 43:1323-1328.
42. Jones JM, Albin RL, Feldman EL, Simin K, Schuster TG, Dunnick WA, Collins JT, Chrisp CE, Taylor BA, Meisler MN. Mnd-2: A new mouse model of inherited motor neuron disease. Genomics 1993, 16:669-677.
43. Tugeon SM, Albin RL. Pharmacology, distribution, cellular localization and development of GABA_B binding in rat cerebellum. Neuroscience 1993, 55:311-323.
44. Kremer BPH, Tallaksen-Greene SJ, Albin RL. AMPA and NMDA binding sites in the hypothalamic lateral tuberal nucleus: Implications for Huntington's disease. Neurology 1993, 43:1593-1595.
45. Curran EJ, Albin RL, Becker JB. Adrenal medulla grafts restore pre- and postsynaptic striatal dopamine symmetry in the hemiparkinsonian rat. J. Neuroscience 1993, 13:3864-3877.
46. Sakurai SY, Lutz PL, Schulman A, Albin RL. Unchanged [³H]MK-801 binding and increased [³H]flunitrazepam binding in turtle forebrain during anoxia. Brain Res 1993, 625:181-185.
47. Strong TV, Table DA, Valdes J, Elmer LW, Boehm K, Swaroop M, Kaatz KW, Collins FS, Albin RL. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nature Genetics 1993, 5:259-265.
48. Albin RL. Antagonistic pleiotropy, mutation accumulation, and human genetic disease. Genetica 1993, 91:279-286.
49. Kuriyama H., Albin RL, Altschuler RA. Expression of NMDA-receptor mRNA in the rat cochlea. Hearing Res. 1993, 69:215-220.
50. Kume A, Sakurai SY, Albin RL. Zinc inhibition of [³H]t-butylbicycloorthobenzoate binding to GABA_A receptor complex. J. Neurochem. 1994, 62:602-607.
51. Juiz JM, Albin RL, Helfert RH, Altschuler RA. Distribution of GABA_A and GABA_B binding sites in the cochlear nucleus of the guinea pig. Brain Research 1994, 639:193-201.
52. Albin RL, Howland MM, Higgins DS, Frey K.A. Autoradiographic quantification of muscarinic cholinergic synaptic markers in bat, shrew, and rat brain. Neurochemical Research 1994, 19:581-589.
53. Veenman CL, Albin RL, Richfield EK, Reiner A. Distributions of GABA_A, GABA_B, and benzodiazepine receptors in the forebrain and midbrain of pigeons. J. Comp. Neurol. 1994, 344:161-189.

54. Bazzett TJ, Becker JB, Falik RC, Albin RL. Chronic intrastriatal quinnolinic acid produces reversible changes in perikaryal calbindin and parvalbumin immunoreactivity. Neuroscience 1994, 60(4):837-841.
55. Tallaksen-Greene SJ, Albin RL. Localization of AMPA-selective excitatory amino acid receptor subunits in identified populations of striatal neurons. Neuroscience 1994, 61(3):509-519.
56. Sakurai SY, Kume A, Burdette DE, Albin RL. Quantitative autoradiography of [³H]-butylbicycloorthobenzoate binding to the gamma-aminobutyric acid receptor_A complex¹. J. Pharm. Exp. Ther. 1994, 270:362-370.
57. Bazzett TJ, Becker JB, Albin RL. Construction and implantation of a chronic intracranial dialytic delivery system. Neuroscience Protocols 1994, 6:1-9.
58. Turgeon SM, Albin RL. Postnatal ontogeny of GABA_B binding in rat brain. Neuroscience 1994, 62:601-613.
59. Aldrich MA, Prokopowicz G, Ockert K, Hollingsworth Z, Penney JB, Albin RL. Neurochemical studies of human narcolepsy: alpha-adrenergic receptor autoradiography of human narcoleptic brain and brainstem. Sleep 1994, 17(7):598-608.
60. Turgeon SM, Albin RL. GABA_B Binding Sites in Aging Rat Brain. Neurobiology of Aging 1994, 15:705-711.
61. Kume A, Albin RL. Quantitative autoradiography of 4'-Ethylnyl-4-n-[2,3-³H₂] propylbicycloorthobenzoate ([³H]EBOB) binding to the GABA_A receptor complex. European Journal of Pharmacology 1994, 263(1-2):163-173.
62. Milbrandt JC, Albin RL, Caspary DM. Age related decrease in GABA_B receptor binding in the Fischer 344 rat inferior colliculus. Neurobiology of Aging 1994, 15(6):699-703.
63. Albin RL, Tagle DA. Genetics and Molecular Biology of Huntington's Disease. TINS 1995, 18(1):11-14.
64. Albin, RL, Young AB, Penney JB. The functional anatomy of disorders of the basal ganglia. TINS 1995, 18(2):63-64.
65. Burdette DE, Sakurai SY, Henry TR, Ross DA, Pennell PB, Frey KA, Sackellares, Albin RL. Temporal Lobe Central Benzodiazepine Binding in Unilateral Mesial Temporal Lobe Epilepsy. Neurology, 1995, 45:934-941.
66. Kaatz KW, Albin RL. Intrastriatal and intrasubthalamic stimulation of metabotropic glutamate receptors: a behavioral and Fos immunohistochemical study. Neuroscience, 1995, 66:55-65.

67. Albin RL. The pathophysiology of chorea/ballism and parkinsonism. Parkinsonism and Related Disorders, 1995, 1:3-11.
68. Synder SE, Kume A, Yong-Woon Jung, Connor SE, Sherman PS, Albin RL, Wieland DM, Kilbourn MR. Synthesis of Carbon-11-, Fluorine-18-, and Iodine-125-Labeled GABA_A-Gated Chlorine Ion Channel Blockers: Substituted 5-tert-Butyl-2-phenyl-1, 3-dithianes and -dithiane Oxides. Journal of Medicinal Chemistry, 1995, 38(38):2663-2671.
69. Galasso JM, Bazzett TJ, Becker JB, Albin RL. Synergistic effect of intrastriatal co-administration of L-NAME and quinolinic acid. NeuroReport 1995, 6:1505-1508.
70. Bazzett TJ, Falik RC, Bekker JB, Albin RL. Chronic Administration of Malonic Acid Produces Selective Neural Degeneration and Transient Changes in Calbindin Immunoreactivity in Rat Striatum. Experimental Neurology 1995, 134:1-10.
71. Albin RL. Editorial: Selective Neurodegeneration in Huntington's disease. Ann Neurol 1995, 38:835-836.
72. Feeley Kearney JA, Albin RL. Adenosine A2 Receptor Mediated Modulation of Contralateral Rotation Induced by Metabotropic Glutamate Receptor Activation in Rats. European Journal of Pharmacology 1995, 287:115-120.
73. Bazzett TJ, Falik RC, Becker JB, Albin RL. Chronic intrastriatal administration of quinolinic acid produces transient nocturnal hypermotility in the rat. Brain Research Bulletin, 1995, 39:69-73.
74. Kaatz KW, Albin RL. Intraseptal Administration of (1S,3R)-1-Aminocyclopentane-1,3-Dicarboxylic Acid Induces Immediate Early Gene Expression in Lateral Septal Neurons. Brain Research. 1996, 709:205-214.
75. Kume A, Greenfield LJ, Jr., Macdonald RL, Albin RL. Felbamate Inhibits [³H]-butylbicycloorthobenzoate Binding and Enhances C1-Current at the γ -aminobutyric Acid_A receptor. Journal of Pharmacology and Experimental Therapeutics, 1996, 277:1784-1792.
76. Fink JK, Rainier S, Wilkowski J, Jones SMM, Kume A, Hedera P, Albin R, Mathay J, Girbach L, Varvil T, Otterud B, Leppert M. Paroxysmal dystonia choreoathetosis: tight linkage to chromosome 2q. American Jour Hum Genet, 1996, 59:140-145.
77. Milbrandt JC, Albin RL, Turgeon SM, Caspary DM. GABA_A Receptor Binding in the Aging Rat Inferior Colliculus. Neuroscience, 1996, 73:449-458.
78. Bazzett TJ, Falik RC, Becker JB, Albin RL. Synergistic Effects of Chronic Exposure to Subthreshold Concentrations of Quinolinic Acid and Malonate in the Rat Striatum. Brain Res, 1996, 718:228-232.

79. Albin RL, Minoshima S, D'Amato C, Frey KA, Kuhl DE, Sima AAF. Fluoro-Deoxyglucose Positron Emission Tomography in Diffuse Lewy Body Disease. Neurology, 1995, 47:462-466.
80. Tallaksen-Greene SJ, Albin RL. Splice Variants of GluR2 and GluR3 Receptor Subunits in Striatal Projection Neurons. Neuroscience, 1996, 75:1057-1064.
81. Frey KA, Koeppe RA, Kilbourn MR, Vander Borgh T, Albin RL, Gilman S, Kuhl DE. Presynaptic Monoaminergic Vesicles in Parkinson's Disease and Normal Aging. Ann Neurol 1996, 40:873-884.
82. Vander Borgh T, Minoshima S, Giordani B, Foster NL, Berent S, Albin RL, Koeppe RA, Kuhl DE. Cerebral Metabolic Differences in Parkinson's and Alzheimer's Diseases Matched for Dementia Severity. J Nuc Med 1997, 38:787-802.
83. Fink JK, Hedera P, Mathay J, Albin RL. Paroxysmal dystonic-choreoathetosis linked to chromosome 2q: Clinical Analysis and Proposed Pathophysiology. Neurology 1997, 49:177-183.
84. Kearney JAF, Frey KA, Albin RL. Metabotropic glutamate agonist-induced rotation: A pharmacologic, FOS immunohistochemical and [¹⁴C]-2-deoxyglucose autoradiographic study. J Neuroscience 1997, 17:4415-4425.
85. Koeppe RA, Frey KA, Kume A, Albin RL, Kilbourn MR, Kuhl DE. Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)- α -[¹¹C]dihydrotetrabenazine (DTBZ) and positron emission tomography. J Cereb Blood Flow Meta 1997, 17:919-931.
86. Ordway JM, Tallaksen-Greene S, Gutekunst C-A, Bernstein E, Wiener HW, Clancy BE, Dure IV LS, Lindsey R, Hersch SM, Jope RS, Albin RL, Detloff PJ. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell 1997, 91:753-763.
87. Bazzett TJ, Geiger A, Coppola B, Albin RL. The neuronal NOS inhibitor L-MIN, but not 7-NINA, reduces neurotoxic effects of chronic intrastriatal administration of quinolinic acid. Brain Res 1997, 775:229-232.
88. Albin RL. Fuch's corneal dystrophy in a patient with mitochondrial DNA mutations. J Med Genet, 1998, 35:258-259.
89. Tallaksen-Greene SJ, Kaatz KW, Romano C, Albin RL. Localization of mGluR1a-like immunoreactivity and mGluR5-like immunoreactivity in identified populations of striatal neurons. Brain Res, 1997, 780:210-217.
90. Shear DA, Dong J, Haik-Creguer KL, Bazzett TJ, Albin RL, Dunbar GL. Chronic intrastriatal administration of quinolinic acid causes spatial learning deficits in a radial arm water maze. Experimental Neurology 1998, 150:305-311.

91. Feeley Kearney JA, Becker JB, Frey KA, Albin RL. The role of nigrostriatal dopamine in metabotropic glutamate agonist-induced rotation. Neuroscience, 1998, 87:881-891.
92. Lavedan C, Buchholtz S, Auburger G, Albin RL, Athanassiadou A, Blancato J, Burguera JA, Ferrell RE, Kostic V, Leroy E, Leube B, Mota-Viera L, Papapetroppoulos T, Pericak-Vance MA, Pinkus J, Scott WK, Ulm G, Vaxconcelos J, Vilchez JJ, Nussbaum RL. Absence of mutation in the beta- and gamma-synuclein genes in familial autosomal dominant Parkinson's disease. DNA Res 5:401-402, 1998.
93. Sprunger LK, Escayg A, Tallaksen-Greene S, Albin RL, Meisler MH. Generalized dystonia associated with mutation of the neuronal sodium channel *Scn8a*: role of the modifier locus *Scnm1* on mouse chromosome 3. Human Molecular Genetics, 8:471-479, 1999.
94. Bohnen NI, Albin RL, Frey KA, Fink JK. (+)- [¹¹C]DTBZ PET imaging in familial paroxysmal dystonic choreoathetosis. Neurology, 52:1067-1069, 1999.
95. Pennell PB, Burdette DE, Ross DA, Henry TR, Albin RL, Sackallares JC, Frey KA. Muscarinic receptor loss with preservation of cholinergic terminals in mesial temporal sclerosis. Epilepsia, 40:38-46, 1999.
96. Bazzett T, Legnard E, Bauter M, Albin RL. Time course analysis and comparison of acute and chronic intrastriatal quinolinic acid administration on forelimb reaching deficits in the rat. Experimental Neurology, 158:126-134, 1999.
97. Meyer P, Bohnen NI, Minoshima S, Koeppe RA, Wernette K, Kilbourn MR, Kuhl DE, Frey KA, Albin RL. Striatal presynaptic monoaminergic vesicles are not increased in Tourette syndrome. Neurology, 53:371-374, 1999.
98. Feeley Kearney JA, Albin RL. Intrasubthalamic nucleus metabotropic glutamate receptor activation: A behavioral, FOS immunohistochemical, and [14C]-2-deoxyglucose autoradiographic study. Neuroscience 95:409-416, 1999.
99. Dickson, DW, Liu W-K, Hardy J, Farrer M, Mehta N, Uitti R, Mark M, Zimmerman T, Globe L, Sage J, D'Amato C, Sima A, Albin R, Gilman S, Yen S-H. Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Path 155:1241-1251, 1999.
100. Bohnen NI, Koeppe RA, Meyer P, Ficaró E, Wernette K, Kilbourn MR, Kuhl DE, Frey KA, Albin RL. Decreased monoaminergic terminals in Huntington's disease. Neurology, 54:1753-1759, 2000.
101. Sullivan AA, Chervin RD, Albin RL. Parkinsonism after rapid correction of hyponatremia with radiological evidence of central pontine myelinolysis and changes in the basal ganglia. J Clin Neurosci, 7:256-259, 2000.

102. Albin RL, Koeppe RA, Chervin RD, Consens FB, Wernette K, Frey KA, Aldrich MS. Decreased Striatal Dopaminergic Innervation in REM Sleep Behavior Disorder. Neurology, 55:1410-1412, 2000.
103. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru M, Kucherlapati M, Fan J, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino S, Mignot E. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nature Med, 6:991-997, 2000.
104. Zhang C, Albin RL. Increased response to intrastriatal L(+)-2-amino-4-phosphonobutyrate (L-2-amino-4-phosphonobutyrate (L-AP4) in unilateral 6-hydroxydopamine lesioned rats. Exp Neurol, 165:278-284, 2000.
105. Kelly KM, Kume A, Albin RL, Macdonald RL. Autoradiography of L-type and N-type calcium channels in aged rat brain. Neurobiol Aging, 22:17-23, 2001.
106. Lin C-H, Tallaksen-Greene S, Chien W-M, Cearley JA, Jackson WS, Crouse AB, Ren S, Li X-J, Albin RL, Detloff PJ. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet, 10:137-144, 2001.
107. Minoshima S, Foster NL, Sima AAF, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 50:358-365, 2001.
108. Suzuki M, Desmond TJ, Albin RL, Frey KA. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers. Synapse 41:329-336, 2001.
109. Suzuki M, Desmond TJ, Albin RL, Frey KA. Cholinergic vesicular transporters in progressive supranuclear palsy. Neurology 58:1013-1018, 2002.
110. Lavedan C, Buchholtz S, Nussbaum RL, Albin RL, Polymeropoulos MH. A mutation in the neurofilament M gene in Parkinson's disease that suggests a role for the cytoskeleton in neuronal degeneration. Neurosci Lett 322:57-61, 2002.
111. Suzuki M, Desmond TJ, Albin RL, Frey KA. Striatal Monoaminergic Terminals in Lewy Body Dementia and Alzheimer Disease. Ann Neurol 51:767-771, 2002.
112. Albin RL. Sham Surgery Controls: Intracerebral grafting of fetal tissue for Parkinson's disease and proposed criteria for use of sham surgery controls. J Med Ethics, 28:322-325, 2002.
113. Kearney JA, Buchner DA, de Haan G, Adamska M, Levin SI, Sprunger L, Furay AR, Albin RL, Jones JM, Montal M, Stevens MJ, Sprunger LK, Meisler MH. Molecular and pathological

- effects of a modifier gene on deficiency of the sodium channel Scn8a (Na_v1.6). Hum Mol Genet, 11:2765-2775, 2002.
114. Albin RL, Frey KA. Initial agonist treatment of Parkinson Disease: A Critique. Neurology, 60:390-394, 2003.
 115. Albin RL, Cross D, Cornblath WT, Wald JA, Wernette K, Frey KA, Minoshima S. Diminished Striatal [¹²³I]Iodobenzovesamicol Binding in Idiopathic Torticollis. Annals of Neurology, 53:528-532, 2003.
 116. Gehring WJ, Bryck RL, Jonides J, Albin RL. The mind's eye, looking inward? In search of executive control in internal attention shifting. Psychophysiology, 40:572-585, 2003.
 117. Kemmerer ES, Desmond TJ, Albin RL, Kilbourn MR, Frey KA. Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: Comparison of L-DOPA and pramipexole. Experimental Neurology 183:81-86, 2003.
 118. Albin RL, Koeppe RA, Bohnen NI, Meyer P, Wernette K, Minoshima S, Kilbourn MR, Frey KA. Increased ventral striatal monoaminergic innervation in Tourette Syndrome. Neurology, 61:310-315, 2003.
 119. Jackson WS, Tallaksen-Greene, SJ, Albin RL, Detloff PD. Nucleocytoplasmic transport signals affect the age of onset of abnormalities in knock-in mice expressing polyglutamine within an ectopic protein context. Hum Mol Genet, 12:1621-1629, 2003.
 120. Tallaksen-Greene SJ, Ordway JM, Crouse AB, Jackson WS, Detloff PJ, Albin RL. Hprt^{(CAG)¹⁴⁶} mice: Age of onset of behavioral abnormalities, time course of neuronal intranuclear inclusion accumulation, neurotransmitter marker alterations, mitochondrial function markers, and susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Comp Neurol, 465:205-219, 2003.
 121. Alb JG Jr, Cortese JD, Phillips SE, Albin RL, Nagy TR, Hamilton BA, Bankaitis VA. Mice lacking phosphatidylinositol transfer protein alpha exhibit spinocerebellar degeneration, intestinal and hepatic steatosis, and hypoglycemia. J Biol Chem, 278:33501-18, 2003.
 122. Bomar JM, Benke PJ, Slattery E, Puttagunta R, Taylor L, Seong E, Nystuen A, Chen W, Albin RL, Patel PD, Kittles RA, Sheffield VC, Burmeister M. Mutations in a novel CRAL-TRIO domain encoding gene cause human Cayman Ataxia and ataxia/dystonia in the jittery mouse. Nat Genet, 35:264-269, 2003.
 123. Lorincz MT, Detloff PJ, Albin RL, O'Shea KS. Embryonic Stem Cells Expressing Expanded CAG Repeats Undergo Aberrant Neuronal Differentiation and Have Persistent Oct-4 and REST/NRSF Expression. Mol Cell Neurosci, 26:135-143, 2004.
 124. Deng YP, Albin RL, Penney JB, Young AB, Anderson KD, Reiner A. Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study. J

- Chem Neuroanat, 27:143-164, 2004.
125. Rainier S, Thomas D, Tokarz D, Ming L, Bui M, Plein E, Zhao X, Lemons R, Albin RL, Delaney C, Alvarado, Fink JK. Myofibrillogenesis regulator 1 (MR-1) gene mutations cause paroxysmal dystonia choreoathetosis. Archives of Neurology, 61:1025-1029, 2004.
 126. Albin RL. Sham surgery controls are mitigated trolleys. J Med Ethics, 31:149-153, 2005.
 127. Tallaksen-Greene, SJ, Crouse AB, Hunter JM, Detloff PJ, Albin RL. Neuronal intranuclear inclusions and neuropil aggregates in *Hdh*^{CAG(150)} knockin mice. Neurosci, 131:843-852, 2005.
 128. Ravina B, Eidelberg D, Ahlskog JE, Albin RL, Brooks DJ, Carbon M, Dhawan V, Feigin A, Fahn S, Guttman M, Gwinn-Hardy K, McFarland H, Innis R, Katz RG, Kieburtz K, Kish SJ, Lange N, Langston JW, Marek K, Morin L, Moy C, Murphy D, Oertel WH, Oliver G, Palesch Y, Powers W, Seibyl J, Sethi KD, Shults CW, Sheehy P, Stoessl AJ, Holloway R. The role of radiotracer imaging in Parkinson's disease. Neurology, 68:208-215, 2005.
 129. Philips ST, Albin RL, Martin DM. Genetics of subthalamic nucleus in development and disease. Exp Neurol, 192:320-330, 2005.
 130. Koeppe RA, Gilman S, Joshi A, Liu S, Little R, Junck L, Heumann M, Frey KA, Albin RL. [¹¹C]DTBZ and [¹⁸F]FDG PET measures in differentiating dementias. J Nuc Med, 46:936-944, 2005.
 131. Albin RL, Koeppe RA. Rapid loss of striatal VMAT2 binding associated with onset of Lewy body dementia. Movement Disorders, 21:287-288, 2006.
 132. Yu Z, Dadgar N, Albertelli M, Scheller A, Albin RL, Robins DM, Lieberman AP. Abnormalities of germ cell maturation and Sertoli cell cytoskeleton in androgen receptor 113 CAG knock-in mice reveal toxic effects of the mutant protein. Am J Path, 168:195-204, 2006.
 133. Mink JW, Albin RL. Recent advances in Tourette syndrome research. Trends in Neurosciences, in press, 2006.
 134. Albin RL. Editorial: Practice parameters for Parkinson disease: Signposts for clinical research. Neurology, in press, 2006.
 135. Bohnen NI, Albin RL, Koeppe RA, Wernette K, Kilbourn MR, Minoshima S, Frey KA. Positron Emission Tomography of Monoaminergic Vesicular Binding in Aging and Parkinson Disease. JCBFM, in press, 2006.

Peer Review Publications; Multicenter Studies

1. Koller WC, Busenbark K, Miner K, Essential Tremor Study Group. The relationship of essential tremor to other movement disorders report on 678 patients. Annals of Neurology, 1993, 6:717-723.

2. Huntington Study Group. The Unified HD Rating Scale: Reliability and Consistency. Movement Disorders, 1996, 11:136-142.
3. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, Hyman B, Crain B, Tang M-X, Phelps C, for the Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. Utility of apolipoprotein E genotype in the diagnosis of Alzheimer's disease. New England J Med 1998, 338:506-511.
4. Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Huntington Study Group. Rate of Functional decline in in Huntington's disease, Neurology 54:452-467, 2000.
5. Huntington Study Group. A randomized, placebo-controlled trial of Co-enzyme Q₁₀ and remacemide in Huntington's disease (CARE-HD). Neurology 57:397-404, 2001.
6. Paulsen JS, Zhao H, Stout JC, Brinkman RR, Guttman M, Ross CA, Como P, Manning C, Hayden MR, Shoulson I, Huntington Study Group. Clinical markers of early disease in persons near onset of Huntington's disease. Neurology 57:658-662, 2001.
7. Wheelock VL, Tempkin T, Marder K, Nance M, Myers RH, Zhao H, Kayson E, Orme C, Shoulson I, and the Huntington Study Group: Predictors of nursing home placement in Huntington disease. Neurology, 60:998-1001, 2003.
8. Parkinson Study Group. Levodopa and the rate of progression of Parkinson disease, the ELLDOPA study. NEJM, 351:2498-2508, 2004.
9. Hogarth P, Kayson E, Kieburtz K, Marder K, Oakes D, Rosas D, Shoulson I, Wexler NS, Young AB, Zhao H, US-Venezuela Huntington's Disease Collaborative Research Group, Huntington Study Group. Interrater agreement in the assessment of motor manifestations of Huntington's disease. Movement Disorders, 20:293-297, 2005.
10. The NINDS NET-PD Investigators. A randomized, double blind, futility clinical trial of creatine and minocycline in early Parkinson's disease. Neurology, 66:664-671, 2006.
11. The NET-PD NPDCS-FS1 Investigators. Utilizing futility designs in Parkinson's disease to optimize the ongoing search for new treatments. Neurology, In Press, 2006.

Non Peer Reviewed Publications

1. Albin RL. HD Research: Progress on All Fronts. The Marker: Huntington's Disease Society of America Newsletter 1994, 7(2):1, 10.
2. Albin RL. Letter: The business of genomics. Nature Genetics, 1996, 14:17.
3. Albin RL. Posterior GPi Pallidotomy. Neurology Network Commentary 1997, 1:99-105.

4. Albin RL. A basal ganglia learning/memory system. Neurol Net Comm, 1997, 1:288-290.
5. Albin RL. A possible mouse model of Huntington's disease. Neurol Net Comm, 1998, 2:19-24.
6. Albin RL. Benefit of early agonist therapy? Neurol Net Comm, 3:1-4, 1999.
7. Albin RL. Compulsive mice. Neurol Net Comm, 3:220-223, 1999.
8. Albin RL. Continuing neurodegeneration in MPTP induced parkinsonism. Neurol Net Comm, in press, 2000.
9. Albin RL, Feeley Kearney JA. Alessandro Agnoli Lecture. Models of basal ganglia dysfunction: predictions and pitfalls. Functional Neurology, 15:135-146, 2000.
10. Albin RL. The End of Lines and Boxes. Mov Dis, 16:405-406, 2001.
11. Albin RL. Does Initial Dopamine Agonist Treatment Prevent Dyskinesias? Lancet Neurol Net, 4;1, 2001.
12. Albin RL. Letter. Samuel Adams' tremor. Neurology 57:1350, 2001.
13. Albin RL, Nichols TE, Frey KA. Letter to Editor: Brain Imaging to Assess the Effects of Dopamine agonists on Progression of Parkinson's disease. JAMA, 288:311-312, 2002.
14. Albin RL. Editorial Commentary. Fetal striatal transplantation in Huntington's disease: time for a pause. J Neurol Neurosurg Psychiatry 73:612, 2002.
15. Minoshima S, Foster NL, Petrie EC, Albin RL, Frey KA, Kuhl DE. Neuroimaging in dementia with Lewy bodies: metabolism, neurochemistry, and morphology. J Geriatr Neurol Psych, 15:200-209, 2002.
16. Albin RL. Dominant ataxias and friedreich ataxia: an update. Current Opinion in Neurology, 16:507-514, 2003.
17. Albin RL. Commentary: Neuroprotective Agents for Clinical Trials in Parkinson's disease; A Public Policy Experiment. Neurology, 60:1225, 2003.
18. Albin RL. Introduction. Exp Neurology, 184:S1, 2003.
19. Feeley Kearney JA, Albin RL. mGluRs: A Target for Pharmacotherapy in Parkinson Disease. Exp Neurol, 184:S30-S36, 2003.
20. Albin RL. Letter to the Editor: Response to Welcome to the Genomic Era. New Eng J Med, 349:2170-2171, 2003.
21. Albin RL. Editorial: A New Hypothesis for Dystonia. Annals of Neurology, 58:5-6, 2005.

Articles Submitted for Publication

1. The Huntington Study Group PHAROS Investigators. At risk for Huntington's disease: The PHAROS (Prospective Huntington At Risk Observational Study) Cohort Enrolled. Archives of Neurology, submitted, 2005.

Chapters in Books

1. Young AB, Albin RL, Penney JB. Neuropharmacology of basal ganglia functions: Relationship to pathophysiology of movement disorders. In: Crossman AR, Sambrook MA, eds. Neural Mechanisms in Disorders of Movement. London, John Libbey, 1989, pp. 17-27.
2. Young AB, Penney JB, Cha J, Olson JMM, Greenamyre JT, Albin RL, Richfield EK. Neuronal and anatomical localization of excitatory amino acid receptor subtypes in vertebrate brain. In: Lehmann J, Turski LA, Caralheiro EA, eds. Frontiers in Excitatory Amino Acid Research, New York, Alan R. Liss, 1988, 46:109-115.
3. Young AB, Cha JJ, Makowiec RL, Albin RL, Penney JB. The anatomy of non-NMDA excitatory amino acid binding sites for EAA. In: Meldrum et al., eds. Excitatory Amino Acids, Vol. 5 Fidia Research Foundation Symposium Series, Raven Press, pp. 55-60.
4. Albin RL, Young AB, Penney JB, Makowiec RL, Gilman S. Chemical neuroanatomy and in vitro receptor autoradiography: A basis for brain positron emission tomography. In: Kuhl DE, ed. In Vivo Imaging of Neurotransmitter Functions in Brain, Heart, and Tumors, Washington, D.C., American College of Nuclear Physicians, 1991, pp. 29-44.
5. Young AB, Sakurai SY, Albin RL, Makowiec R, Penney JB. Excitatory amino acid receptor distribution: quantitative autoradiographic studies. In: Wheal H and Thomson A, eds. Excitatory amino acids and synaptic function, Academic Press, 1990.
6. Albin RL, Hollingsworth Z, Sakurai SY, Makowiec RL, Higgins DS, Dure LS, Penney JB, Young AB. Excitatory amino acid binding sites in the basal ganglia, primary visual cortex, and spinal cord. In: Simon RP, ed. Excitatory Amino Acids, Thieme Publishers Inc., New York, 1992, pp. 179-181.
7. Albin RL. The basal ganglia. In: Beaumont JG, Sargent J, eds. Dictionary of Neuropsychology, Oxford (in press).
8. Albin RL. Antagonistic pleiotropy, mutation accumulation, and human genetic disease. In: Genetics and Evolution of Aging, Kluwer Academic Publishers, 1993, pp. 307-314.
9. Albin RL, Frey KA. Chemical neurotransmission. In: Albin MS, ed. Textbook of Neuroanesthesia, McGraw-Hill, New York, 1996, pp. 521-540.

10. Frey KA, Albin RL. Receptor Binding Techniques. In: Gerfen CR, Ed. Current Protocols in Neurobiology, Wiley Interscience.
11. Shah S, Albin RL.. Movement Disorders. In: Shah S, Kelly KM, eds. Emergency Neurology: Principles and Practice, Cambridge University Press, New York, 1999, pp 232-252.
12. Albin RL, Wald JJ. The Motor System. In: Gilman S, ed. Clinical Examination of the Nervous System, McGraw-Hill, New York, 1999, pp. 113-157.
13. Albin RL. The Pathophysiology of Parkinsonism and Dyskinesias. In Krauss J, Grossman R, Jankovic J, eds. Pallidotomy for the Treatment of Parkinson's Disease and Movement Disorders, Lippincott-Raven, Philadelphia, 1998, pp. 41-52.
14. Albin RL. Functional anatomy and pharmacology of the basal ganglia. In: Gilman S, Goldstein GW, Waxman SG, eds. Neurobase, San Diego: Arbor Publishing, 1999.
15. Bazzett T, Albin RL, Becker JB. Malonic acid and the chronic administration model of excitotoxicity. In: Borlongon CV, Sanberg P, Nishino H, eds. Mitochondrial Inhibitors as Tools for Neurobiology, Humana, Totowa, NJ, 1999, pp. 219-231.
16. Albin RL. Basal Ganglia Neurotoxins. In: Albers JW, Berent S, eds. Neurologic Clinics of North America, 18:665-680, 2000.
17. Bazzett T, Albin RL. Huntington Disease: A Model Excitotoxic Chronic Neurodegeneration. In: Palomo T, Beninger RJ, Archer T, eds. Neurodegenerative Brain Disorders, 2001, pp. 259-288.
18. Lorincz MT, Albin RL. Trinucleotide Repeat Disorders. In: Gilman S, Goldstein GW, Waxman SG, eds. Medlink Neurology, San Diego: Arbor Publishing, 2001.
19. Schwarcz R, Albin RL. Huntington's Disease. In: Lodge D, Dansyz W, Parsons CG, eds. Iontropic Glutamate Receptors as Therapeutic Targets, Johnson City, TN: FP Graham, 2002, pp. 587-610.
20. Albin RL. Neurobiology of basal ganglia and Tourette syndrome. In: Walkup, ed. Tourette Syndrome, In Press, 2004.

Abstracts

1. Albin RL, Greenberg HS, Townsend JB, Burke JM, Alessi AG, Albers JW. Acute sensory neuropathy from pyridoxine overdose. Neurology, 36 (Suppl 1):175, 1986.
2. Greenamyre JT, Albin RL, Penney JB, Young AB. Autoradiographic localization of amino acid receptors in rat and human spinal cord. Soc. Neurosci. Abstr., 11:111, 1985.

3. Albin RL, Reiner A, Anderson KD, D'Amato CJ, Penney JB, Young AB. Differential loss of substance-P and enkephalin-containing striatofugal projections in adult-onset and juvenile-onset Huntington's disease. Soc. Neurosci. Abstr., 13:1361, 1987.
4. Young AB, Albin RL, Albin MS, Penney JB, Greenamyre JT, Maragos WF. 1,2,3,4-tetrahydroamino-9-acridine and other acridine derivatives are displacers of specifically bound (3H)-N-(1-(2-thienyl)cyclohexyl)-3,4-piperidine. Soc. Neurosci. Abstr., 13:1553, 1987.
5. Albin RL, Reiner A, Anderson KD, D'Amato CJ, Penney JB, Young AB. Juvenile-onset Huntington's disease: Two cases studied with immunocytochemistry, cholinesterase histochemistry, and autoradiography. Neurology 38 (Suppl. 1):360, 1988.
6. Young AB, Penney JB, Richfield EK, Albin RL, Dauth G, Gilman S. Anatomy of excitatory amino acid receptors in developing and adult mammalian nervous system. Neurochem. Int. 12(Suppl. 1):2, 1988.
7. Albin RL, Richfield EK, Reiner A, Penney JB, Young AB. The distribution of glutamate, GABA, benzodiazepine, muscarinic, and opiate receptors in the avian tectum. Soc. Neurosci. Abstr. 14:56, 1988.
8. Richfield EK, Albin RL, Reiner A, Young AB, Penney JB. Receptor binding patterns in the basal ganglia of pigeons. Soc. Neurosci. Abstr. 14:1022, 1988.
9. Young AB, Greenamyre JT, Hollingsworth Z, Albin R, D'Amato CJ, Shoulson I, Penney JB. NMDA receptor losses in Huntington's disease putamen support a neurotoxic hypothesis. Soc. Neurosci. Abstr. 14:419, 1988.
10. Ewald E, Albin RL, Vanderzant CW, Gebarski SS, McCune WJ. Clinical features and spectrum of disease of isolated angiopathy of the central nervous system (IACNS). Arthritis and Rheumatism 31:S-120, 1988.
11. Ewald E, Albin RL, Vanderzant CW, Gebarski SS, McCune WJ. Magnetic resonance imaging (MRI) abnormalities in isolated angiopathy of the central nervous system (IACNS). Arthritis and Rheumatism 31:S-120, 1988.
12. Albin RL. The death of Nicholas Bolkonski: Neurology in Tolstoy's *War and Peace*. Neurology 39 (Suppl. 1):281, 1989.
13. Albin RL, Young AB, Reiner A, Anderson KD, Handelin B, Markel D, Penney JB, Tourtellotte WW. N-methyl-D-Aspartate receptor and enkephalin abnormalities in a case of presymptomatic Huntington's disease. Neurology 39 (Suppl. 1):423, 1989.
14. Albin RL, Cha JJ, Makowiec R, Young AB, Gilman S, Plaitakis A. Autoradiographic analysis of cerebellar amino acid neurotransmitter receptors in olivopontocerebellar atrophy and Friedreich's ataxia. Neurology 39(Suppl. 1):423, 1989.

15. Albin RL, Richfield EK, Reiner A, Young AB, Penney JB. Autoradiographic localization of amino acid neurotransmitter receptors in the cerebellar cortex of pigeon (*Columba livia*) and turtle (*Pseudemys scripta*). Soc. Neurosci. Abstr. 15:407, 1989.
16. Albin RL, Penney JB, Young AB. Loss of enkephalinergic striatal-lateral pallidal projections and NMDA receptors in early Huntington's disease. IIIrd International Basal Ganglia Society Meeting, 1990.
17. Cha JJ, Makowiec RL, Albin RL, Penney JB, Young AB. L-[³H] glutamate labels the metabotropic excitatory amino acid receptor in mammalian brain. Neurochemistry International 16 (Suppl 1):23, 1990.
18. Aldrich ML, Hollingsworth Z, Albin RL, Penney JB. Dopamine receptor autoradiographic studies of postmortem human narcoleptic brain Sleep Res. 19:180, 1990.
19. Aldrich ML, Frey K, Albin RL, Penney JB. Muscarinic receptor autoradiographic studies of postmortem human brain. Sleep Res. 19:179, 1990.
20. Sakurai SY, Albin RL, Reiner A, Young AB. [³H]MK-801 binding in pigeon forebrain. Soc. Neurosci. Abstr. 16:90, 1990.
21. Albin RL, Makowiec RL, Hollingsworth Z, Dure LS, Penney JB, Young AB. Excitatory amino acid receptors in rat basal ganglia. Soc. Neurosci. Abstr. 16:1233, 1990.
22. Higgins DS, Albin RL, Penney JB, Young AB. N-methyl-D-aspartate receptors in bats and shrews. Soc. Neurosci. Abstr. 16:90, 1990.
23. Young AB, Sakurai SY, Albin RL [³H]MK-801 and NMDA-sensitive [³H] glutamate binding in turtle brain. Soc. Neurosci. Abstr. 16:90, 1990.
24. Howland MM, Higgins DS, Albin RL, Frey KA. Autoradiographic analysis of pre- and post-synaptic muscarinic cholinergic pathways in bat, shrew and rat brain. Soc. Neurosci. Abstr. 16:1058, 1990.
25. Maragos WF, Albin RL, Sakurai SY, Makowiec RL, Higgins DS, Young AG, Penney AB. Excitatory and inhibitory amino acid receptors in human striate cortex. Soc. Neurosci. Abstr. 16:1191, 1990.
26. Bazzett T, Becker JB, Albin RL. Chronic intrastriatal administration of high and low dose quinolinic acid using a novel device for dialytic delivery. Soc. Neurosci. Abstr. 17:787, 1991.
27. Bazzett T, Becker JB, Albin RL. Selective neuronal loss produced by chronic intrastriatal delivery of quinolinic acid via microdialysis. Third IBRO World Congress of Neuroscience 353, 1991.
28. Becker JB, Bazzett T, Albin RL. Sex difference in striatal dopamine receptor binding. Soc. Neurosci. Abstr. 17:269, 1991.

29. Turgeon S, Albin RL, Gilman S. Development, pharmacology distribution, and cellular localization of GABA_B binding in rat cerebellum. Soc. Neurosci. Abstr. 17:1572, 1991.
30. Kincaid AE, Albin RL, Newman SW, Penney JB, Young AB. Dopaminergic regulation of glutamic acid decarboxylase mRNA in pallidal projection neurons. Soc. Neurosci. Abstr. 17:854, 1991.
31. Albin AL, Price RH, Sakurai SY, Penney JB, Young AB. Excitatory and inhibitory amino acid binding sites in human dentate nucleus. Soc. Neurosci. Abstr. 17:1572, 1991.
32. Bazzett T, Becker JB, Albin RL. Chronic intrastriatal dialytic administration of quinolinic acid reveals selective sparing of NADPH-Diaphorase neurons. Soc. Neurosci. Abstr. 18:442, 1992.
33. Sakurai SY, Burdette DE, Albin RL. Chronic autoradiography of [³H] TBOB binding to GABA_A receptors. Soc. Neurosci. Abstr. 18:665, 1992.
34. Turgeon SM, Albin RL. Ontogeny of GABA_B binding in rat brain. Soc. Neurosci. Abstr. 18:356, 1992.
35. Tallaksen-Greene SJ, Wiley RG, Albin RL. Localization of Striatal excitatory amino acid binding site subtypes to striatonigral projection neurons. Soc. Neurosci. Abstr. 18:1042, 1992.
36. Kuriyama H, Albin R, Shiosaka S, Altschuler RA. Expression of NMDA-receptor mRNA in the rat auditory system. Soc. Neurosci. Abstr. 18:1992, 1992.
37. Burdette DE, Sakurai SY, Sackallares JC, Henry TR, Ross DA, Gilman S, Frey KA, Albin RL. GABA_A receptor binding and central benzodiazepine omega 1 and omega 2 receptor binding in mesial temporal lobe epilepsy. Neurology (in press).
38. Aldrich MS, Ockert K, Albin RL. Alpha-1 adrenergic receptor autoradiography of human narcoleptic brainstem. Neurology (in press).
39. Tallaksen-Green SJ, Albin RL. Localization of ampa-selective excitatory amino acid receptor subunits in subpopulations of striatal neurons. Soc. Neurosci. Abstr. 19:130, 1993.
40. Albin RL, Kaatz KW. Intrastriatal injection of (1S, 3R)-ACPD produces FOS-immunoreactive neurons in the basal ganglia. Soc. Neurosci. Abstr. 19:131, 1993.
41. Bazzett TJ, Albin RL, Becker JB, Falik RC. Neuronal dysfunction secondary to chronic exposure of quinolinic acid. Soc. Neurosci. Abstr. 19:1346, 1993.
42. Milbrandt JC, Albin RL, Caspary DM. Effects of aging on GABA_A and glycine receptor binding the inferior colliculus and cochlear nucleus of the fischer 344 rat: A quantitative autoradiographic study. Soc. Neurosci. Abstr. 19:1425, 1993.

43. Kaatz KW, Albin RL. Metabotropic glutamate receptor activation induces intermediate early gene expression in dorsolateral septal neurons. Soc. Neurosci. Abstr. 20(1):278, 1994.
44. Kume A, Albin RL. Quantitative autoradiography of 4'-Ethynyl-4-n-[2,3-³H₂] propylbicycloorthobenzoate ([³H]EBOB) binding to the GABA_{AA} receptor complex. Soc. Neurosci. Abstr. 20(1):501, 1994.
45. Turgeon SM, Albin RL. GABA_B Binding Sites in Aging Rat Brain. Soc. Neurosci. Abstr. 20(1):881, 1994.
46. Tallaksen-Greene SJ, Albin RL. Localization of "flip" and "flop" splice variants of AMPA-selective GluR2 and GluR3 excitatory amino acid receptor subunits on striatal projection neurons. Soc. Neurosci. Abstr. 20(2):989, 1994.
47. Bazzett T, Trahey C, Ugarte S, Becker J, Albin R. Chronic bilateral intrastriatal dialytic administration of quinolinic acid produces abnormal motor behavior in rats. Soc. Neurosci. Abstr. 20(2):1255, 1994.
48. Vander Borcht TM, Desmond TJ, Kilbourn MR, Albin RL, Koeppe RA, Kuhl DE, Frey KA. Evaluation of methosytetabenazine as in vivo tracer of monoamine nerve terminal integrity. J. Nucl. Med. 1994; 35 (5):121P.
49. Pennell PB, Burdette DE, Henry TR, Ross DA, Sackkellares JC, Albin RL, Frey KA: Hippocampal muscarinic receptor binding in mesial temporal lobe epilepsy. Neurology 1994;44 (Suppl. 2):A176-A177.
50. Feeley Kearney J, Albin RL. Modulation of metabotropic glutamate agonist induced rotation by adenosine agonists and antagonists. Soc. Neurosci. Abstr., 21:2079, 1995.
51. Kume A, Albin RL. Autoradiographic study of felbamate effects on GABA_A and NMDA receptors. Soc. Neurosci. Abstr., 21:2116, 1995.
52. Minoshima S, Frey KA, Biordani, BL, Foster NL, Koeppe RA, Berent S, Albin RL, Kuhl DE. Technical Feasibility and Initial Diagnostic Application of Functional Brain Image Database System in Dementia. Society of Nuclear Medicine, in press, 1996.
53. Fink JK, Rainier S, Wilcowski J, Jones SM, Kume A, Hedera P, Albin RL, Mathay J, Girbach L, Lesicki A, Reinglass T, Pahade N, Varvil T, Otterud B, Leppert M. Paroxysmal dystonic-choreoathetosis:tight linkage to chromosome 2q. American Society of Human Genetics, in press, 1996.
54. Kelly, KM, Kume A, Albin RL, Macdonald RM. Autoradiography of L-type calcium channels in aged rat brain. Soc. Neurosci. Abstr., 22:6, 1996.
55. Feeley Kearney, J. and Albin RL. Metabotropic Glutamate Agonist-Induced Rotation Mediated by Group I mGluRs. Soc. Neurosci. Abstr., 22:600, 1996.

56. Giordani B, Persad CC, Messmer C, Sima AAF, Gilman S, Albin RL, Foster NL, Huemann ME, Kluin M, Berent S. Lewy Body Disease Differs from Alzheimer's Disease in Neuropsychological Profile. JINS 1996; 3:15.
57. Shear D, Dong J, Haik-Creguer KL, Bazzett TJ, Albin RL, Dunbar GL. Chronic intrastriatal administration of quinolinic acid produces cognitive deficits in a rodent model of Huntington's disease. Soc. Neurosci. Abstr., 23:1908, 1997.
58. Tallaksen-Greene SJ, Ordway J, Detloff P, Albin RL. Histological effects of an expanded CAG-repeat insertion into the mouse *Hprt* gene. Tallaksen-Greene SJ, Ordway J, Detloff P, Albin RL. Soc. Neurosci. Abstr., 23:1623, 1997.
59. Feeley Kearney JA, Becker JB, Albin RL. The effects of unilateral 6-hydroxydopamine lesions and aging on metabotropic glutamate agonist-induced rotation. Soc. Neurosci. Abstr., 23:2030, 1997.
60. Meyer P, Bohnen NI, Minoshima S, Wernette K, Koeppe RA, Kilbourn MA, Kuhl DE, Frey KA, Albin RL. Presynaptic monoaminergic vesicles in Tourette syndrome studied by (+)-[C-11]DTBZ PET. Soc. Nuclear Med., in press.
61. Bohnen NI, Meyer P, Koeppe RA, Kilbourn MR, Kuhl DE, Frey KA. Decreased striatal monoaminergic terminals in Huntington's disease demonstrated with (+)-[C-11]DTBZ PET. Soc. Nuclear Med., in press.
62. Frey KA, Bohnen NI, Meyer P, Elmer L, Albin RL, Koeppe RA, Kilbourn MR, Kuhl DE. (+)-[C-11]DTBZ PET imaging of presynaptic monoaminergic vesicles in isolated postural tremor. Soc. Nuclear Med., in press.
63. Bohnen NI, Meyer P, Albin RL, Minoshima S, Wernette K, Koeppe RA, Kilbourn MR, Kuhl DE, Frey KA. Clinical correlates of striatal (+)-[C-11]DTBZ binding to VMAT2 in Parkinson's disease. Soc. Nuclear Med., in press.
64. Shaw BA, Nyquist LV, Liang J, Albin R, Heidebrink J. Recruiting normal controls for Alzheimer's disease research involving brain autopsy. Gerontologist 1999;39(special issue 1):365-366.
65. Bohnen NI, Minoshima S, Kilbourn MR, Koeppe RA, Frey KA, Kuhl DA, Albin RL. Presynaptic monoaminergic vesicular transporter imaging in Tourette syndrome using (+)-[11C]DTBZ-PET. Neurology 52(Suppl 2):A176.
66. Murrell JR, Miravalle L, Foster NL, Albin R, Takao M, Ghetti B. Early-onset familial Alzheimer disease from the first American report: a presenilin-1 (PS1) mutation found in descendants. J. Neuropathol. Exp. Neurol., 2001;60:543.

67. Lorincz MT, O'Shea KS, Detloff PD, Albin RL. Neuronally differentiated embryonic stem cells as a Huntington's disease model. Soc. Neurosci. Abstr. 27: 52, 2001.
68. Tallaksen-Greene SJ, Detloff PD, Albin RL. Susceptibility of mitochondrial toxins in a murine model of CAG repeat disorders. Soc. Neurosci. Abstr. 27: 224, 2001.
69. Suzuki M, Desmond TJ, Albin RL, Gilman S, Frey KA. Presynaptic cholinergic and dopaminergic markers in Lewy body dementia. Soc. Neurosci. Abstr. 27: 497, 2001.
70. Albin RL, Frey KA, Kilbourn M, Koeppe RA. Dopaminergic and cholinergic vesicular imaging in hyperkinetic movement disorders. Dopamine 2002, 195.
71. Jackson WS, Tallaksen-Greene S, Albin RL, Detloff PJ. Will a nuclear export signal or a nuclear localization signal alter the toxicity of a pathogenic polyglutamine protein in the mouse? Soc. Neurosci. Abstr., 2002.
72. Albin RL, Koeppe RA, Bohnen NI, Minoshima S, Kilbourn MA, Frey KA. Increased ventral striatal monoaminergic innervation in Tourette syndrome. Soc. Neurosci. Abstr., 2002.
73. Bomar J, Benke PJ, Slattery E, Puttagunta R, Taylor L, Seong E, Nystuen A, Chen W, Albin RL, Patel P, Kittles RA, Sheffield VC. Identification of the Cayman Ataxia gene via the mouse mutant jittery: A novel neuron-specific CRAL-TRIO domain protein. Amer Soc Human Genetics, in press, 2003.
74. Gilman S, Frey KA, Koeppe RA, Albin RL, Junck L, Heumann M, Wernette K. Differences between idiopathic Parkinson's disease and dementia with Lewy bodies detected with [¹¹C]dihydrotrabenazine and positron emission tomography. Mov Disord 2004;19:S373.

Revised February, 2006